Can Mounjaro Affect Your Heart?

What happens to heart rate on Mounjaro?

One of the most consistently reported cardiovascular signals in Mounjaro trials is a small increase in resting heart rate. Across the SURMOUNT programme (which involved thousands of adults treated with tirzepatide over 72 weeks) participants at the higher doses saw average increases of roughly 2–4 beats per minute compared with placebo. That is modest for most people, and for the majority of participants it did not translate into symptoms or require any change to their treatment.

The mechanism sits with tirzepatide's dual action on GIP and GLP-1 receptors, both of which interact with the autonomic nervous system. A slightly elevated resting rate is a recognised class effect across GLP-1-based medicines, not something unique to Mounjaro. For healthy adults, a 2–4 bpm increase is unlikely to be clinically meaningful. For someone already managing a heart-rhythm condition, it is a different conversation, one that belongs with their GP or cardiologist before a prescription is considered. You can read more about how tirzepatide interacts with cardiovascular physiology on our Mounjaro and heart health overview.

If you find yourself noticing a noticeably faster heartbeat after starting or increasing your dose, that is worth flagging to your prescriber rather than waiting. It does not automatically mean you need to stop, but your clinical team should know.

Does Mounjaro carry any risk of serious cardiovascular harm?

Based on the available trial data, tirzepatide has not been shown to increase the risk of major adverse cardiovascular events, the category that includes heart attack, stroke and cardiovascular death. The SURMOUNT-1 trial, published in the New England Journal of Medicine, reported no significant difference in serious cardiac events between the tirzepatide and placebo groups across its 72-week follow-up. Cardiovascular safety data from the larger SURPASS diabetes programme points in a similarly reassuring direction.

For comparison, semaglutide (the active ingredient in Wegovy) has gone further: a separate dedicated cardiovascular outcomes trial demonstrated a statistically significant reduction in major cardiovascular events in adults with obesity and established heart disease. Tirzepatide has not yet completed a similarly designed outcomes trial, so the full cardiovascular benefit picture remains an active area of research rather than settled fact. What can be said is that no increase in risk has been found, which is meaningfully different from saying the question is closed.

People with decompensated heart failure or certain serious arrhythmias may not be suitable candidates, and the prescriber will ask about these conditions directly. The specific question of heart-rate changes on Mounjaro is covered in more depth if that is what you came here to explore.

What about blood pressure and the wider cardiovascular picture?

One area where Mounjaro's cardiovascular story becomes more clearly positive is blood pressure. Across the SURMOUNT trials, tirzepatide at all active doses produced meaningful reductions in systolic blood pressure (often in the range of 6–10 mmHg over the course of treatment) compared with placebo. Since sustained high blood pressure is itself a major driver of cardiovascular risk, this is a clinically relevant finding, not just a side note.

Improvements in lipid profiles were also observed: lower triglycerides and modest improvements in LDL and HDL cholesterol. These are indirect markers, not outcome data, but they add to the picture of metabolic improvement that typically accompanies significant weight loss, whatever method achieves it. The Mounjaro overview page sets out the broader mechanism and evidence base if you want the fuller context. For questions about how Mounjaro interacts with other organ systems, the pages on its effects on the liver and its effects on the kidneys may also be useful.

The NHS patient information for tirzepatide, available via NHS.uk, lists heart palpitations and increased heart rate among the side effects to report if they are troubling. That remains a sensible guide to what warrants a call to your prescriber versus what you can monitor yourself.

How to think through this decision practically

The question most people are really asking is not an abstract one about trial statistics. It is: given my personal cardiac history, is it safe for me to start? That question genuinely cannot be answered by a webpage, and this one will not pretend otherwise. What the evidence supports is a working picture: for people without a significant cardiac history, the cardiovascular signals from Mounjaro trials are either neutral or tilted slightly positive; for those with existing heart conditions, the clinical picture needs individual review.

One practical detail worth mentioning: because Mounjaro is stored in the fridge, many people keep their pen on the door shelf, the same shelf where temperature fluctuates most. The SmPC recommends the main body of the fridge for this reason, not the door. Small thing, but worth noting.

If you are also considering the cost context alongside the clinical picture, the Mounjaro pricing page explains what a private prescription typically includes and what the transparent pricing at nume covers. The relevant question about alcohol and cardiovascular risk is addressed on the drinking on Mounjaro page. For a fuller view of what treatment through a clinician-led service looks like, the weight-loss treatment overview is the clearest starting point, and our clinical team's approach is outlined on the clinical team profile.

If you have a specific cardiac history and want a prescriber to review your situation properly, a free consultation with our team is the right next step. A real clinician reads every submission the same day, not software, not a checklist without oversight. Speak to our prescribers when you are ready.